Drug Approval | May 06, 2024
Briefs: Eugia Pharma Specialities and IOL Chemicals and Pharmaceuticals
Eugia Pharma Specialities receives 7 observations from USFDA for Unit II
Eugia Pharma Specialities receives 7 observations from USFDA for Unit II
Wipro's MPPP360 platform will assist Independent Health in streamlining the payment process to seamlessly integrate these new provisions
GAAP net loss of $1.2 billion and GAAP diluted EPS of $(3.07)
New advanced technology-enabled offering aims to streamline synthetic route identification for novel active pharmaceutical ingredients (APIs)
The QC Lab is equipped with advanced instruments to ensure rigorous quality control across all manufacturing processes
Parexel will leverage Palantir’s Foundry and Artificial Intelligence Platform to further power its clinical data platform
The drug will be manufactured at the group's topical manufacturing facility at Changodar, Ahmedabad (India)
The proposed facility is expected to be operational around January, 2027
One form of thalidomide has the intended sedative effect but the opposite mirror-image form interferes with foetal development
Desidustat, administered orally is a novel, oral Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor (HIF-PHI) for treating anaemia in Chronic Kidney Disease (CKD) patients
Subscribe To Our Newsletter & Stay Updated
